Skip to main content
SpringerLink
Log in

Acute Myeloid Leukemia

  • Chapter
Molecular Pathology in Clinical Practice

  • 3672 Accesses

Abstract

The diagnostic entity of acute myeloid leukemia (AML) encompasses a heterogeneous group of diseases whose prognosis differs substantially according to the nature of the underlying molecular lesions and the age of the patient. AML is predominantly a disease of the elderly with a dramatic increase in incidence in individuals over 60 years of age. Traditionally, cases of AML have been classified as primary (de novo) or secondary including those arising following exposure to radiation and various chemotherapeutic agents (therapy-related AML), or occurring on a background of an antecedent hematologic disorder, particularly myelodysplasia.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.

    Google Scholar 

  2. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–51.

    Article  CAS  PubMed  Google Scholar 

  3. de Thé H, Chomienne C, Lanotte M, et al. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus. Nature. 1990;347(6293):558–61.

    Article  PubMed  Google Scholar 

  4. Borrow J, Goddard AD, Sheer D, et al. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science. 1990;249(4976):1577–80.

    Article  CAS  PubMed  Google Scholar 

  5. Goddard AD, Borrow J, Freemont PS, et al. Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science. 1991;254(5036):1371–4.

    Article  CAS  PubMed  Google Scholar 

  6. Brown NJ, Ramalho M, Pedersen EW, et al. PML nuclear bodies in the pathogenesis of acute promyelocytic leukemia: active players or innocent bystanders? Front Biosci. 2009;14:1684–707.

    Article  CAS  Google Scholar 

  7. Grimwade D, Biondi A, Mozziconacci M-J, et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Blood. 2000;96(4):1297–308.

    CAS  PubMed  Google Scholar 

  8. Chen Z, Brand NJ, Chen A, et al. Fusion between a novel Krüppel-like zinc finger gene and the retinoic acid receptor-α locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J. 1993;12(3):1161–7.

    Google Scholar 

  9. Redner RL, Rush EA, Faas S, et al. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood. 1996;87(3):882–6.

    CAS  PubMed  Google Scholar 

  10. Wells RA, Catzavelos C, Kamel-Reid S. Fusion of retinoic acid receptor α to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nat Genet. 1997;17(1):109–13.

    Article  CAS  PubMed  Google Scholar 

  11. Kondo T, Mori A, Darmanin S, et al. The seventh pathogenic fusion gene FIP1L1-RARA was isolated from a t(4;17)-positive acute promyelocytic leukemia. Haematologica. 2008;93(9):1414–6.

    Article  CAS  PubMed  Google Scholar 

  12. Yamamoto Y, Tsuzuki S, Tsuzuki M, et al. BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia. Blood. 2010;116(20):4274–83.

    Article  CAS  PubMed  Google Scholar 

  13. Catalano A, Dawson MA, Somana K, et al. The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia. Blood. 2007;110(12):4073–6.

    Article  CAS  PubMed  Google Scholar 

  14. Arnould C, Philippe C, Bourdon V, et al. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor α in acute promyelocytic-like leukaemia. Hum Mol Genet. 1999;8(9):1741–9.

    Google Scholar 

  15. Grimwade D, Mistry AR, Solomon E, et al. Acute promyelocytic leukemia: a paradigm for differentiation therapy. Cancer Treat Res. 2010;145:219–35.

    Article  CAS  PubMed  Google Scholar 

  16. Licht JD, Chomienne C, Goy A, et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood. 1995;85(4):1083–94.

    CAS  PubMed  Google Scholar 

  17. Dong S, Tweardy DJ. Interactions of STAT5b-RARα, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways. Blood. 2002;99(8):2637–46.

    Article  CAS  PubMed  Google Scholar 

  18. Zhang X-W, Yan X-J, Zhou Z-R, et al. Arsenic trioxide controls the fate of the PML-RARα oncoprotein by directly binding PML. Science. 2010;328(5975):240–3.

    Article  CAS  PubMed  Google Scholar 

  19. Goyama S, Mulloy JC. Molecular pathogenesis of core binding factor leukemia: current knowledge and future prospects. Int J Hematol. 2011;94(2):126–33.

    Article  CAS  PubMed  Google Scholar 

  20. Martens JHA, Stunnenberg HG. The molecular signature of oncofusion proteins in acute myeloid leukemia. FEBS Lett. 2010;584(12):2662–9.

    Article  CAS  PubMed  Google Scholar 

  21. De Braekeleer E, Férec C, De Braekeleer M. RUNX1 translocations in malignant hemopathies. Anticancer Res. 2009;29(4):1031–7.

    PubMed  Google Scholar 

  22. Guastadisegni MC, Lonoce A, Impera L, et al. CBFA2T2 and C20orf112: two novel fusion partners of RUNX1 in acute myeloid leukemia. Leukemia. 2010;24(8):1516–9.

    Article  CAS  PubMed  Google Scholar 

  23. Slovak ML, Bedell V, Popplewell L, et al. 21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: report from an International Workshop. Genes Chromosomes Cancer. 2002;33(4):379–94.

    Article  PubMed  Google Scholar 

  24. Ottone T, Hasan SK, Montefusco E, et al. Identification of a potential "hotspot" DNA region in the RUNX1 gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation. Genes Chromosomes Cancer. 2009;48(3):213–21.

    Article  CAS  PubMed  Google Scholar 

  25. Meyer C, Hofmann J, Burmeister T, et al. The MLL recombinome of acute leukemias in 2013. Leukemia. 2013;27(11):2165–76.

    Google Scholar 

  26. Smith E, Lin C, Shilatifard A. The super elongation complex (SEC) and MLL in development and disease. Genes Dev. 2011;25(7):661–72.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Rubnitz JE, Raimondi SC, Tong X, et al. Favorable impact of the t(9;11) in childhood acute myeloid leukemia. J Clin Oncol. 2002;20(9):2302–9.

    Article  CAS  PubMed  Google Scholar 

  28. Mrózek K, Heinonen K, Lawrence D, et al. Adult patients with de novo acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocations involving band 11q23: a Cancer and Leukemia Group B study. Blood. 1997;90(11):4532–8.

    PubMed  Google Scholar 

  29. Beverloo HB, Le Coniat M, Wijsman J, et al. Breakpoint heterogeneity in t(10;11) translocation in AML-M4/M5 resulting in fusion of AF10 and MLL is resolved by fluorescent in situ hybridization analysis. Cancer Res. 1995;55(19):4220–4.

    CAS  PubMed  Google Scholar 

  30. Klaus M, Schnittger S, Haferlach T, et al. Cytogenetics, fluorescence in situ hybridization, and reverse transcriptase polymerase chain reaction are necessary to clarify the various mechanisms leading to an MLL-AF10 fusion in acute myelocytic leukemia with 10;11 rearrangement. Cancer Genet Cytogenet. 2003;144(1):36–43.

    Article  CAS  PubMed  Google Scholar 

  31. Bloomfield CD, Archer KJ, Mrózek K, et al. 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an International Workshop. Genes Chromosomes Cancer. 2002;33(4):362–78.

    Article  PubMed  Google Scholar 

  32. Felix CA, Kolaris CP, Osheroff N. Topoisomerase II and the etiology of chromosomal translocations. DNA Repair (Amst). 2006;5(9-10):1093–108.

    Article  CAS  Google Scholar 

  33. Soekarman D, von Lindern M, Daenen S, et al. The translocation (6;9)(p23;q34) shows consistent rearrangement of two genes and defines a myeloproliferative disorder with specific clinical features. Blood. 1992;79(11):2990–7.

    CAS  PubMed  Google Scholar 

  34. Xu S, Powers MA. Nuclear pore proteins and cancer. Semin Cell Dev Biol. 2009;20(5):620–30.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Secker-Walker LM, Mehta A, Bain B. Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study. Br J Haematol. 1995;91(2):490–501.

    Article  CAS  PubMed  Google Scholar 

  36. Morishita K, Parker DS, Mucenski ML, et al. Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell. 1988;54(6):831–40.

    Article  CAS  PubMed  Google Scholar 

  37. Du Y, Jenkins NA, Copeland NG. Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. Blood. 2005;106(12):3932–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. Stein S, Ott MG, Schultze-Strasser S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med. 2010;16(2):198–204.

    Article  CAS  PubMed  Google Scholar 

  39. Mrózek K, Heinonen K, Bloomfield CD. Clinical importance of cytogenetics in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001;14(1):19–47.

    Article  PubMed  CAS  Google Scholar 

  40. Mercher T, Le Coniat MB, Monni R, et al. Involvement of a human gene related to the Drosophila spen gene in the recurrent t(1;22) translocation of acute megakaryocytic leukemia. Proc Natl Acad Sci USA. 2001;98(10):5776–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  41. Ma Z, Morris SW, Valentine V, et al. Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat Genet. 2001;28(3):220–1.

    Article  CAS  PubMed  Google Scholar 

  42. Cheng E-C, Luo Q, Bruscia EM, et al. Role for MKL1 in megakaryocytic maturation. Blood. 2009;113(12):2826–34.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  43. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials. Blood. 2010;116(3):354–65.

    Article  CAS  PubMed  Google Scholar 

  44. Mrózek K, Heinonen K, Theil KS, et al. Spectral karyotyping in patients with acute myeloid leukemia and a complex karyotype shows hidden aberrations, including recurrent overrepresentation of 21q, 11q, and 22q. Genes Chromosomes Cancer. 2002;34(2):137–53.

    Article  PubMed  Google Scholar 

  45. Galván AB, Mallo M, Arenillas L, et al. Does monosomy 5 really exist in myelodysplastic syndromes and acute myeloid leukemia? Leuk Res. 2010;34(9):1242–5.

    Article  PubMed  CAS  Google Scholar 

  46. Yoneda-Kato N, Look AT, Kirstein MN, et al. The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene. 1996;12(2):265–75.

    CAS  PubMed  Google Scholar 

  47. Mrózek K, Holland KB, Pettenati MJ, et al. Prognostic significance of unbalanced chromosome abnormalities used by 2008 World Health Organization (WHO) classification to define “acute myeloid leukemia (AML) with myelodysplasia-related changes” in adults: a Cancer and Leukemia Group B (CALGB) study. Blood. 2009;114(22):1021 (abstract 2602).

    Google Scholar 

  48. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98(6):1752–9.

    Article  CAS  PubMed  Google Scholar 

  49. Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079–89.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  50. Bacher U, Haferlach T, Kern W, et al. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica. 2007;92(6):744–52.

    Article  CAS  PubMed  Google Scholar 

  51. Mead AJ, Linch DC, Hills RK, et al. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood. 2007;110(4):1262–70.

    Article  CAS  PubMed  Google Scholar 

  52. Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909–18.

    Article  CAS  PubMed  Google Scholar 

  53. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100(1):59–66.

    Article  CAS  PubMed  Google Scholar 

  54. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326–35.

    Article  CAS  PubMed  Google Scholar 

  55. Bacher U, Haferlach C, Kern W, et al. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters – an analysis of 3082 patients. Blood. 2008;111(5):2527–37.

    Article  CAS  PubMed  Google Scholar 

  56. Whitman SP, Ruppert AS, Radmacher MD, et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood. 2008;111(3):1552–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  57. Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a Cancer and Leukemia Group B study. Cancer Res. 2001;61(19):7233–9.

    CAS  PubMed  Google Scholar 

  58. Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111(5):2776–84.

    Article  CAS  PubMed  Google Scholar 

  59. Green CL, Koo KK, Hills RK, et al. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol. 2010;28(16):2739–47.

    Article  CAS  PubMed  Google Scholar 

  60. Taskesen E, Bullinger L, Corbacioglu A, et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood. 2011;117(8):2469–75.

    Article  CAS  PubMed  Google Scholar 

  61. Bienz M, Ludwig M, Oppliger Leibundgut E, et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res. 2005;11(4):1416–24.

    Article  CAS  PubMed  Google Scholar 

  62. Dufour A, Schneider F, Metzeler KH, et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol. 2010;28(4):570–7.

    Article  CAS  PubMed  Google Scholar 

  63. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352(3):254–66.

    Article  CAS  PubMed  Google Scholar 

  64. Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005;106(12):3733–9.

    Article  CAS  PubMed  Google Scholar 

  65. Döhner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106(12):3740–6.

    Article  PubMed  CAS  Google Scholar 

  66. Verhaak RGW, Goudswaard CS, van Putten W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood. 2005;106(12):3747–54.

    Article  CAS  PubMed  Google Scholar 

  67. Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006;107(10):4011–20.

    Article  CAS  PubMed  Google Scholar 

  68. Becker H, Marcucci G, Maharry K, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28(4):596–604.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  69. Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010;28(22):3636–43.

    Article  CAS  PubMed  Google Scholar 

  70. Boissel N, Nibourel O, Renneville A, et al. Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol. 2010;28(23):3717–23.

    Article  CAS  PubMed  Google Scholar 

  71. Marcucci G, Maharry K, Wu Y-Z, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28(14):2348–55.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  72. Green CL, Evans CM, Zhao L, et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood. 2011;118(2):409–12.

    Article  CAS  PubMed  Google Scholar 

  73. Boissel N, Nibourel O, Renneville A, et al. Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood. 2011;117(13):3696–7.

    Article  CAS  PubMed  Google Scholar 

  74. Chou W-C, Chou S-C, Liu C-Y, et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood. 2011;118(14):3803–10.

    Google Scholar 

  75. Gaidzik VI, Paschka P, Späth D, et al. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML Study Group. J Clin Oncol. 2012;30(12):1350–7.

    Article  CAS  PubMed  Google Scholar 

  76. Weissmann S, Alpermann T, Grossmann V, et al. Landscape of TET2 mutations in acute myeloid leukemia. Leukemia. 2012;26(5):934–42.

    Article  CAS  PubMed  Google Scholar 

  77. Metzeler KH, Maharry K, Radmacher MD, et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2011;29(10):1373–81.

    Article  PubMed Central  PubMed  Google Scholar 

  78. Ribeiro AFT, Pratcorona M, Erpelinck-Verschueren C, et al. Mutant DNMT3A: a new marker of poor prognosis in acute myeloid leukemia. Blood. 2012;119(24):5824–31.

    Article  CAS  PubMed  Google Scholar 

  79. Thol F, Damm F, Ludeking A, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol. 2011;29(21):2889–96.

    Article  CAS  PubMed  Google Scholar 

  80. Marcucci G, Metzeler KH, Schwind S, et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2012;30(7):742–50.

    Article  PubMed Central  PubMed  Google Scholar 

  81. Renneville A, Boissel N, Nibourel O, et al. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia. 2012;26(6):1247–54.

    Article  CAS  PubMed  Google Scholar 

  82. Chou W-C, Huang H-H, Hou H-A, et al. Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood. 2010;116(20):4086–94.

    Article  CAS  PubMed  Google Scholar 

  83. Pratcorona M, Abbas S, Sanders MA, et al. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. Haematologica. 2012;97(3):388–92.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  84. Rocquain J, Carbuccia N, Trouplin V, et al. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer. 2010;10:401.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  85. Metzeler KH, Becker H, Maharry K, et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood. 2011;118(26):6920–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  86. Grossmann V, Tiacci E, Holmes AB, et al. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood. 2011;118(23):6153–63.

    Google Scholar 

  87. Li M, Collins R, Jiao Y, et al. Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemia. Blood. 2011;118(22):5914–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  88. Van Vlierberghe P, Patel J, Abdel-Wahab O, et al. PHF6 mutations in adult acute myeloid leukemia. Leukemia. 2011;25(1):130–4.

    Article  PubMed  CAS  Google Scholar 

  89. Yoo NJ, Kim YR, Lee SH. Somatic mutation of PHF6 gene in T-cell acute lymphoblatic leukemia, acute myelogenous leukemia and hepatocellular carcinoma. Acta Oncol. 2012;51(1):107–11.

    Article  CAS  PubMed  Google Scholar 

  90. Caligiuri MA, Strout MP, Lawrence D, et al. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res. 1998;58(1):55–9.

    CAS  PubMed  Google Scholar 

  91. Schnittger S, Kinkelin U, Schoch C, et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia. 2000;14(5):796–804.

    Article  CAS  PubMed  Google Scholar 

  92. Döhner K, Tobis K, Ulrich R, et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol. 2002;20(15):3254–61.

    Article  PubMed  CAS  Google Scholar 

  93. Caligiuri MA, Strout MP, Schichman SA, et al. Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res. 1996;56(6):1418–25.

    CAS  PubMed  Google Scholar 

  94. Whitman SP, Ruppert AS, Marcucci G, et al. Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. Blood. 2007;109(12):5164–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  95. Whitman SP, Caligiuri MA, Maharry K, et al. The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia. Leukemia. 2012;26(7):1713–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  96. Gaidzik VI, Bullinger L, Schlenk RF, et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol. 2011;29(10):1364–72.

    Article  PubMed  Google Scholar 

  97. Schnittger S, Dicker F, Kern W, et al. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood. 2011;117(8):2348–57.

    Article  CAS  PubMed  Google Scholar 

  98. Mendler JH, Maharry K, Radmacher MD, et al. RUNX1 mutations associate with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene- and microRNA-expression signatures. J Clin Oncol. 2012;30(25):3109–18.

    Google Scholar 

  99. Cairoli R, Beghini A, Grillo G, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias. An Italian retrospective study. Blood. 2006;107(9):3463–8.

    Article  CAS  PubMed  Google Scholar 

  100. Schnittger S, Kohl TM, Haferlach T, et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood. 2006;107(5):1791–9.

    Article  CAS  PubMed  Google Scholar 

  101. Boissel N, Leroy H, Brethon B, et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia. 2006;20(6):965–70.

    Article  CAS  PubMed  Google Scholar 

  102. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B study. J Clin Oncol. 2006;24(24):3904–11.

    Article  CAS  PubMed  Google Scholar 

  103. Care RS, Valk PJM, Goodeve AC, et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol. 2003;121(5):775–7.

    Article  CAS  PubMed  Google Scholar 

  104. Haferlach C, Dicker F, Herholz H, et al. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia. 2008;22(8):1539–41.

    Article  CAS  PubMed  Google Scholar 

  105. Rücker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012;119(9):2114–21.

    Article  PubMed  CAS  Google Scholar 

  106. Renneville A, Boissel N, Zurawski V, et al. Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association. Cancer. 2009;115(16):3719–27.

    Article  CAS  PubMed  Google Scholar 

  107. Virappane P, Gale R, Hills R, et al. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2008;26(33):5429–35.

    Article  CAS  PubMed  Google Scholar 

  108. Gaidzik VI, Schlenk RF, Moschny S, et al. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood. 2009;113(19):4505–11.

    Article  CAS  PubMed  Google Scholar 

  109. Paschka P, Marcucci G, Ruppert AS, et al. Wilms’ tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2008;26(28):4595–602.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  110. Becker H, Marcucci G, Maharry K, et al. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010;116(5):788–92.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  111. Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009;27(4):504–10.

    Article  CAS  PubMed  Google Scholar 

  112. Bowen DT, Frew ME, Hills R, et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood. 2005;106(6):2113–9.

    Article  CAS  PubMed  Google Scholar 

  113. Bacher U, Haferlach T, Schoch C, et al. Implications of NRAS mutations in AML: a study of 2502 patients. Blood. 2006;107(10):3847–53.

    Article  CAS  PubMed  Google Scholar 

  114. Neubauer A, Maharry K, Mrózek K, et al. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol. 2008;26(28):4603–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  115. Reindl C, Quentmeier H, Petropoulos K, et al. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. Clin Cancer Res. 2009;15(7):2238–47.

    Article  CAS  PubMed  Google Scholar 

  116. Ghassemifar R, Thien CB, Finlayson J, et al. Incidence of c-Cbl mutations in human acute myeloid leukaemias in an Australian patient cohort. Pathology. 2011;43(3):261–5.

    Article  CAS  PubMed  Google Scholar 

  117. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059–74.

    Article  CAS  Google Scholar 

  118. Thol F, Bollin R, Gehlhaar M, et al. Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. Blood. 2014;123(6):914–20.

    Article  CAS  PubMed  Google Scholar 

  119. Kon A, Shih LY, Minamino M, et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet. 2013;45(10):1232–7.

    Article  CAS  PubMed  Google Scholar 

  120. Taskesen E, Havermans M, van Lom K, et al. Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling. Blood. 2014;123(21):3327–35.

    Article  CAS  PubMed  Google Scholar 

  121. Je EM, Yoo NJ, Kim YJ, et al. Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors. Int J Cancer. 2013;133(1):260–5.

    Google Scholar 

  122. Zhang S-J, Rampal R, Manshouri T, et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood. 2012;119(19):4480–5.

    Google Scholar 

  123. Herold T, Metzeler KH, Vosberg S, et al. Isolated trisomy 13 defines a genetically homogenous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis. Blood. 2014;124(8):1304–11.

    Google Scholar 

  124. Fasan A, Eder C, Haferlach C, et al. GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis. Leukemia. 2013;27(2):482–5.

    Article  CAS  PubMed  Google Scholar 

  125. Green CL, Tawana K, Hills RK, et al. GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations. Br J Haematol. 2013;161(5):701–5.

    Article  CAS  PubMed  Google Scholar 

  126. Greif PA, Dufour A, Konstandin NP, et al. GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. Blood. 2012;120(2):395–403.

    Google Scholar 

  127. Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10(12):1911–8.

    CAS  PubMed  Google Scholar 

  128. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97(8):2434–9.

    Article  CAS  PubMed  Google Scholar 

  129. Rosnet O, Bühring HJ, Marchetto S, et al. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia. 1996;10(2):238–48.

    CAS  PubMed  Google Scholar 

  130. Levis M, Small D. FLT3: ITDoes matter in leukemia. Leukemia. 2003;17(9):1738–52.

    Article  CAS  PubMed  Google Scholar 

  131. Kayser S, Schlenk RF, Londono MC, et al. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood. 2009;114(12):2386–92.

    Article  CAS  PubMed  Google Scholar 

  132. Meshinchi S, Alonzo TA, Stirewalt DL, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood. 2006;108(12):3654–61.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  133. Pratz KW, Sato T, Murphy KM, et al. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood. 2010;115(7):1425–32.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  134. Fröhling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100(13):4372–80.

    Article  PubMed  CAS  Google Scholar 

  135. Choudhary C, Schwäble J, Brandts C, et al. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood. 2005;106(1):265–73.

    Article  CAS  PubMed  Google Scholar 

  136. Gale RE, Hills R, Kottaridis PD, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood. 2005;106(10):3658–65.

    Article  CAS  PubMed  Google Scholar 

  137. Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012;9(10):579–90.

    Article  CAS  PubMed  Google Scholar 

  138. Knapper S. The clinical development of FLT3 inhibitors in acute myeloid leukemia. Expert Opin Investig Drugs. 2011;20(10):1377–95.

    Article  CAS  PubMed  Google Scholar 

  139. Tang J-L, Hou H-A, Chen C-Y, et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood. 2009;114(26):5352–61.

    Article  CAS  PubMed  Google Scholar 

  140. Pabst T, Mueller BU, Zhang P, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia. Nat Genet. 2001;27(3):263–70.

    Article  CAS  PubMed  Google Scholar 

  141. Nerlov C. C/EBPα mutations in acute myeloid leukaemias. Nat Rev Cancer. 2004;4(5):394–400.

    Article  CAS  PubMed  Google Scholar 

  142. Pabst T, Mueller BU. Complexity of CEBPA dysregulation in human acute myeloid leukemia. Clin Cancer Res. 2009;15(17):5303–7.

    Article  CAS  PubMed  Google Scholar 

  143. Smith ML, Cavenagh JD, Lister TA, et al. Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med. 2004;351(23):2403–7.

    Article  CAS  PubMed  Google Scholar 

  144. Pabst T, Eyholzer M, Haefliger S, et al. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. J Clin Oncol. 2008;26(31):5088–93.

    Article  CAS  PubMed  Google Scholar 

  145. Kirstetter P, Schuster MB, Bereshchenko O, et al. Modeling of C/EBPα mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. Cancer Cell. 2008;13(4):299–310.

    Article  CAS  PubMed  Google Scholar 

  146. Bereshchenko O, Mancini E, Moore S, et al. Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPα mutant AML. Cancer Cell. 2009;16(5):390–400.

    Article  CAS  PubMed  Google Scholar 

  147. Preudhomme C, Sagot C, Boissel N, et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood. 2002;100(8):2717–23.

    Article  CAS  PubMed  Google Scholar 

  148. Fröhling S, Schlenk RF, Stolze I, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol. 2004;22(4):624–33.

    Article  PubMed  CAS  Google Scholar 

  149. Marcucci G, Maharry K, Radmacher MD, et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B study. J Clin Oncol. 2008;26(31):5078–87.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  150. Wouters BJ, Löwenberg B, Erpelinck-Verschueren CAJ, et al. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood. 2009;113(13):3088–91.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  151. Pabst T, Eyholzer M, Fos J, et al. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. Br J Cancer. 2009;100(8):1343–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  152. Renneville A, Boissel N, Gachard N, et al. The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication. Blood. 2009;113(21):5090–3.

    Article  CAS  PubMed  Google Scholar 

  153. Falini B. Acute myeloid leukemia with mutated nucleophosmin (NPM1): molecular, pathological, and clinical features. Cancer Treat Res. 2010;145:149–68.

    Article  CAS  PubMed  Google Scholar 

  154. Schnittger S, Kern W, Tschulik C, et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood. 2009;114(11):2220–31.

    Article  CAS  PubMed  Google Scholar 

  155. Krönke J, Schlenk RF, Jensen K-O, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian Acute Myeloid Leukemia Study Group. J Clin Oncol. 2011;29(19):2709–16.

    Article  PubMed  Google Scholar 

  156. Vassiliou GS, Cooper JL, Rad R, et al. Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice. Nat Genet. 2011;43(5):470–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  157. Mrózek K, Marcucci G, Paschka P, et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood. 2007;109(2):431–48.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  158. Haferlach C, Mecucci C, Schnittger S, et al. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood. 2009;114(14):3024–32.

    Article  CAS  PubMed  Google Scholar 

  159. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11):1058–66.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  160. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–73.

    Google Scholar 

  161. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17(3):225–34.

    Google Scholar 

  162. Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010;207(2):339–44.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  163. Löwenberg B. Genetic markers in relation to the therapeutic management of acute myeloid leukemia. Hematology Education. 2011;5:36–41.

    Google Scholar 

  164. Thol F, Damm F, Wagner K, et al. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood. 2010;116(4):614–6.

    Article  CAS  PubMed  Google Scholar 

  165. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553–67.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  166. Moran-Crusio K, Reavie L, Shih A, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011;20(1):11–24.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  167. Ko M, Huang Y, Jankowska AM, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 2010;468(7325):839–43.

    Google Scholar 

  168. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424–33.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  169. Shen Y, Zhu Y-M, Fan X, et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood. 2011;118(20):5593–603.

    Google Scholar 

  170. Hou H-A, Kuo Y-Y, Liu C-Y, et al. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood. 2012;119(2):559–68.

    Article  CAS  PubMed  Google Scholar 

  171. Marková J, Michková P, Burčková K, et al. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia. Eur J Haematol. 2012;88(2):128–35.

    Article  PubMed  CAS  Google Scholar 

  172. Gelsi-Boyer V, Trouplin V, Adélaïde J, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009;145(6):788–800.

    Article  CAS  PubMed  Google Scholar 

  173. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453–74.

    Article  PubMed  CAS  Google Scholar 

  174. Béné MC, Nebe T, Bettelheim P, et al. Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10. Leukemia. 2011;25(4):567–74.

    Article  PubMed  Google Scholar 

  175. Grimwade D. Screening for core binding factor gene rearrangements in acute myeloid leukemia. Leukemia. 2002;16(5):964–9.

    Article  CAS  PubMed  Google Scholar 

  176. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113(9):1875–91.

    Article  CAS  PubMed  Google Scholar 

  177. Freeman SD, Jovanovic JV, Grimwade D. Development of minimal residual disease-directed therapy in acute myeloid leukemia. Semin Oncol. 2008;35(4):388–400.

    Article  CAS  PubMed  Google Scholar 

  178. Grimwade D, Hills RK. Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Edu Program. 2009;385–95.

    Google Scholar 

  179. Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999;17(12):3767–75.

    CAS  PubMed  Google Scholar 

  180. Byrd JC, Ruppert AS, Mrózek K, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol. 2004;22(6):1087–94.

    Article  CAS  PubMed  Google Scholar 

  181. Burnett AK. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? An adult treater’s view. Br J Haematol. 2002;118(2):357–64.

    Article  PubMed  Google Scholar 

  182. Cornelissen JJ, van Putten WLJ, Verdonck LF, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. 2007;109(9):3658–66.

    Article  CAS  PubMed  Google Scholar 

  183. Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and metaanalysis of prospective clinical trials. JAMA. 2009;301(22):2349–61.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  184. Haferlach C, Alpermann T, Schnittger S, et al. Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype. Blood. 2012;119(9):2122–5.

    Article  CAS  PubMed  Google Scholar 

  185. Breems DA, Van Putten WLJ, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26(29):4791–7.

    Article  PubMed  Google Scholar 

  186. Mrózek K. Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype. Semin Oncol. 2008;35(4):365–77.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  187. Medeiros BC, Othus M, Fang M, et al. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood. 2010;116(13):2224–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  188. Fang M, Storer B, Estey E, et al. Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation. Blood. 2011;118(6):1490–4.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  189. Raimondi SC, Chang MN, Ravindranath Y, et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood. 1999;94(11):3707–16.

    CAS  PubMed  Google Scholar 

  190. von Neuhoff C, Reinhardt D, Sander A, et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol. 2010;28(16):2682–9.

    Article  CAS  Google Scholar 

  191. Harrison CJ, Moorman AV, Hills RK, et al. Cytogenetics of childhood acute myeloid leukemia: 753 patients in UK Medical Research Council treatment trials, AML 10 and 12. J Clin Oncol. 2010;28(16):2674–81.

    Article  PubMed  Google Scholar 

  192. Coenen EA, Raimondi SC, Harbott J, et al. Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. Blood. 2011;117(26):7102–11.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  193. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5):1312–20.

    Article  CAS  PubMed  Google Scholar 

  194. Farag SS, Archer KJ, Mrózek K, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006;108(1):63–73.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  195. Fröhling S, Schlenk RF, Kayser S, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood. 2006;108(10):3280–8.

    Article  PubMed  CAS  Google Scholar 

  196. Schoch C, Haferlach T, Haase D, et al. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol. 2001;112(1):118–26.

    Article  CAS  PubMed  Google Scholar 

  197. Farag SS, Maharry K, Zhang M-J, et al. Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients aged 60–70 years with acute myeloid leukemia in first remission. Biol Blood Marrow Transplant. 2011;17(12):1796–803.

    Article  PubMed  Google Scholar 

  198. Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA. 2010;107(16):7473–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  199. Perrot A, Luquet I, Pigneux A, et al. Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities. Blood. 2011;118(3):679–85.

    Article  CAS  PubMed  Google Scholar 

  200. Burnett AK, Grimwade D, Solomon E, et al. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood. 1999;93(12):4131–43.

    CAS  PubMed  Google Scholar 

  201. Lugthart S, van Drunen E, van Norden Y, et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood. 2008;111(8):4329–37.

    Article  CAS  PubMed  Google Scholar 

  202. Hollink IHIM, van den Heuvel-Eibrink MM, Arentsen-Peters STCJM, et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood. 2011;118(13):3645–56.

    Article  CAS  PubMed  Google Scholar 

  203. Akiki S, Dyer SA, Grimwade D, et al. NUP98-NSD1 fusion in association with FLT3-ITD mutation identifies a prognostically relevant subgroup of pediatric acute myeloid leukemia patients suitable for monitoring by real time quantitative PCR. Genes Chromosomes Cancer. 2013;52(11):1053–64.

    Google Scholar 

  204. Grimwade D, Vyas P, Freeman S. Assessment of minimal residual disease in acute myeloid leukemia. Curr Opin Oncol. 2010;22(6):656–63.

    Article  PubMed  Google Scholar 

  205. Grimwade D, Walker H, Oliver F, et al. What happens subsequently in AML when cytogenetic abnormalities persist at bone marrow harvest? Results of the 10th UK MRC AML trial. Bone Marrow Transplant. 1997;19(11):1117–23.

    Article  CAS  PubMed  Google Scholar 

  206. Marcucci G, Mrózek K, Ruppert AS, et al. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from Cancer and Leukemia Group B study 8461. J Clin Oncol. 2004;22(12):2410–8.

    Article  PubMed  Google Scholar 

  207. Chen Y, Cortes J, Estrov Z, et al. Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. J Clin Oncol. 2011;29(18):2507–13.

    Article  PubMed  Google Scholar 

  208. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010;11(6):543–52.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  209. Maurillo L, Buccisano F, Del Principe MI, et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol. 2008;26(30):4944–51.

    Article  PubMed  Google Scholar 

  210. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642–9.

    Article  PubMed  Google Scholar 

  211. Lo Coco F, Diverio D, Avvisati G, et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood. 1999;94(7):2225–9.

    CAS  PubMed  Google Scholar 

  212. Esteve J, Escoda L, Martín G, et al. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. Leukemia. 2007;21(3):446–52.

    Article  CAS  PubMed  Google Scholar 

  213. Meloni G, Diverio D, Vignetti M, et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RARα fusion gene. Blood. 1997;90(3):1321–5.

    CAS  PubMed  Google Scholar 

  214. Lo-Coco F, Romano A, Mengarelli A, et al. Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease. Leukemia. 2003;17(10):1930–3.

    Article  CAS  PubMed  Google Scholar 

  215. Yin JAL, Grimwade D. Minimal residual disease evaluation in acute myeloid leukaemia. Lancet. 2002;360(9327):160–2.

    Google Scholar 

  216. Gabert J, Beillard E, van der Velden VHJ, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia—a Europe Against Cancer program. Leukemia. 2003;17(12):2318–57.

    Google Scholar 

  217. Hehlmann R, Grimwade D, Simonsson B, et al. The European LeukemiaNet: achievements and perspectives. Haematologica. 2011;96(1):156–62.

    Article  PubMed Central  PubMed  Google Scholar 

  218. Grimwade D, Jovanovic JV, Hills RK, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol. 2009;27(22):3650–8.

    Article  CAS  PubMed  Google Scholar 

  219. Ommen HB, Schnittger S, Jovanovic JV, et al. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1–RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood. 2010;115(2):198–205.

    Article  CAS  PubMed  Google Scholar 

  220. Falini B, Martelli MP, Tiacci E, et al. Immunohistochemical surrogates for genetic alterations of CCDN1, PML, ALK, and NPM1 genes in lymphomas and acute myeloid leukemia. Best Pract Res Clin Haematol. 2010;23(3):417–31.

    Article  CAS  PubMed  Google Scholar 

  221. van Dongen JJM, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 concerted action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13(12):1901–28.

    Google Scholar 

  222. Flora R, Grimwade D. Real-time quantitative RT-PCR to detect fusion gene transcripts associated with AML. Methods Mol Med. 2004;91:151–73.

    CAS  PubMed  Google Scholar 

  223. Gorello P, Cazzaniga G, Alberti F, et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia. 2006;20(6):1103–8.

    Article  CAS  PubMed  Google Scholar 

  224. White HE, Matejtschuk P, Rigsby P, et al. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood. 2010;116(22):e111–7.

    Article  CAS  PubMed  Google Scholar 

  225. Dawson MA, Prinjha RK, Dittmann A, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011;478(7370):529–33.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  226. Harris WJ, Huang X, Lynch JT, et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell. 2012;21(4):473–87.

    Article  CAS  PubMed  Google Scholar 

  227. Schenk T, Chen WC, Göllner S, et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med. 2012;18(4):605–11.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  228. Kentsis A, Reed C, Rice KL, et al. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med. 2012;18(7):1118–22.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  229. Kohlmann A, Klein H-U, Weissmann S, et al. The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories. Leukemia. 2011;25(12):1840–8.

    Article  CAS  PubMed  Google Scholar 

  230. Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107(9):3469–73.

    Article  CAS  PubMed  Google Scholar 

  231. Gröschel S, Sanders MA, Hoogenboezem R, et al. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell. 2014;157(2):369–81.

    Google Scholar 

  232. Yamazaki H, Suzuki M, Otsuki A, et al. A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. Cancer Cell. 2014;25(4):415–27.

    Google Scholar 

  233. Rampal R, Alkalin A, Madzo J, et al. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Rep. 2014;9(5):1841–55.

    Google Scholar 

  234. Wang Y, Xiao M, Chen X, et al. WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation. Mol Cell. 2015;57(4):662–73.

    Google Scholar 

  235. Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111–21.

    Google Scholar 

Download references

Acknowledgments

We are indebted to Alan Burnett, Nigel Russell, Robert Hills, Rosemary Gale, David Linch, and members of the UK National Cancer Research Institute (NCRI) AML Working Group for their assistance in providing relevant data. DG gratefully acknowledges the National Institute for Health Research (NIHR) for the support for molecular diagnostics and assessment of minimal residual disease in the UK NCRI AML17 trial. This paper presents independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research (Grant Reference Number RP-PG-0108-10093). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. In addition, D.G. grateful acknowledges research funding from Leukaemia & Lymphoma Research of Great Britain, the Guy’s and St. Thomas’ Charity, and the MRD Workpackage (WP12) of the European LeukemiaNet. K.M. thanks Clara D. Bloomfield for her continuous help and encouragement and gratefully acknowledges the support from the Coleman Leukemia Research Foundation.

Author information

Authors and Affiliations

  1. Department of Medical and Molecular Genetics, Cancer Genetics Laboratory, King’s College London, Faculty of Life Sciences and Medicine, 8th Floor, Tower Wing, Guy’s Hospital Campus, London, SE1 9RT, UK

    David Grimwade Ph.D., F.R.C.Path.

  2. Department of Haematology, Cardiff University, Cardiff, UK

    Steven Knapper D.M., B.M.B.Ch., F.R.C.Path.

  3. Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA

    Krzysztof Mrózek M.D., Ph.D.

Authors
  1. David Grimwade Ph.D., F.R.C.Path.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven Knapper D.M., B.M.B.Ch., F.R.C.Path.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Krzysztof Mrózek M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Grimwade Ph.D., F.R.C.Path. .

Editor information

Editors and Affiliations

  1. Pathology and Laboratory Medicine, University of Vermont College of Medicine and University of Vermont Medical Center, Burlington, Vermont, USA

    Debra G.B. Leonard

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Grimwade, D., Knapper, S., Mrózek, K. (2016). Acute Myeloid Leukemia. In: Leonard, D. (eds) Molecular Pathology in Clinical Practice. Springer, Cham. https://doi.org/10.1007/978-3-319-19674-9_40

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-19674-9_40

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-19673-2

  • Online ISBN: 978-3-319-19674-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation